Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

European cannabis company merges with Canadian grower Aqualitas

Cannaray Limited has signed a definitive agreement to merge with Aqualitas Inc. Aqualitas has developed a cultivation system using living soil and aquaponic fertilization from the nutrient-dense waste of 3,000 koi carp fish, which has produced award-winning medical cannabis products.

Aqualitas is joining forces with Cannaray's medical cannabis divisions, Therismos GmbH (Germany) and Therismos Limited (UK). Therismos partners with opinion leaders in pain, psychiatry, and other indications to provide patients with the ideal cannabis therapy and dosing guidelines. In Germany, Therismos has a partnership with Walgreens Boots Alliance's German subsidiary Alliance Healthcare/GEHE, which has 4,000 cooperation partner pharmacies in the 'Alphega' and 'gesund leben' network. In the UK, Therismos has an established medical cannabis dispensing pharmacy and medical cannabis clinic.

With the recent cannabis legalization changes in Germany, this merger positions the combined entity uniquely in the market, creating a global, vertically integrated business to bring consistent, high-quality, and cost-effective medication to the patient.

Last year, the combined companies generated sales of US$51M. This merger delivers the promise of even greater growth through vertical integration, a vast distribution network, and unique, high-quality, Clean Green-certified organic medical cannabis products.

M. Scott Maguire, CEO of Cannaray, expresses excitement for the future, stating, "We are delighted to have found Aqualitas, a company that has developed products with the patient at the forefront and shares our commitment to excellence. We are positioned to play a leading role in Germany, where the German market is expected to grow exponentially as a result of the impending declassification of cannabis from a narcotic to a non-narcotic. We will be one of the few European companies with a seed-to-shelf operation in the UK and Germany."

Myrna L. Gillis, CEO of Aqualitas, remarks, "This international merger with Cannaray is a significant milestone, reflecting our dedication to excellence in manufacturing clean, consistent, and safe medical cannabis products. Together, we share a vision of delivering the best medication in a variety of formats to provide physicians and patients the best therapeutic options."

For more information:

Cannaray, Therismos

Publication date: